TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Aprea Therapeutics ( (APRE) ).
On November 12, 2025, Aprea Therapeutics reported its third-quarter financial results and provided updates on its clinical programs. The company highlighted progress in its WEE1 and ATR inhibitor programs, with APR-1051 showing promising results in a Phase 1 trial and ATRN-119 reaching a recommended Phase 2 dose. Aprea’s financials showed a reduction in operating loss and R&D expenses compared to the previous year, with cash reserves expected to support operations into late 2026.
The most recent analyst rating on (APRE) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Underperform.
Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company’s strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments that target specific cancer cell vulnerabilities while minimizing harm to healthy cells. The company’s lead programs include APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both aimed at treating solid tumor indications.
Average Trading Volume: 70,965
Technical Sentiment Signal: Sell
Current Market Cap: $7.4M
See more insights into APRE stock on TipRanks’ Stock Analysis page.